List of Excipients in Branded Drug QBREXZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Journey Medical Corporation	QBREXZA	glycopyrronium	69489-411	ALCOHOL	2033-02-28
Journey Medical Corporation	QBREXZA	glycopyrronium	69489-411	ANHYDROUS CITRIC ACID	2033-02-28
Journey Medical Corporation	QBREXZA	glycopyrronium	69489-411	TRISODIUM CITRATE DIHYDRATE	2033-02-28
Journey Medical Corporation	QBREXZA	glycopyrronium	69489-411	WATER	2033-02-28

Last updated: August 7, 2026

Qbrexza is a differentiated topical anticholinergic product built around a single-use cloth, not a conventional cream or gel. Its commercial opportunity is strongest in formulation engineering, pediatric usability, lower-irritation delivery, unit-dose packaging, and follow-on topical products. The main barriers are clinical equivalence, anticholinergic safety, applicator design, manufacturing controls, and any remaining Orange Book or non-Orange Book patent rights.

Qbrexza Excipient Strategy and Commercial Opportunities

What is Qbrexza and how does its formulation work?

Qbrexza is a prescription topical cloth containing glycopyrronium tosylate, equivalent to glycopyrronium, for primary axillary hyperhidrosis in adults and pediatric patients aged 9 years and older. The product received FDA approval in 2018 and is applied once daily to each underarm using a premoistened single-use cloth.[1]

The product’s commercial differentiation comes from controlled topical delivery rather than from a new pharmacologic mechanism. Glycopyrronium is an anticholinergic agent that reduces eccrine sweat production by inhibiting cholinergic stimulation of sweat glands.

Product attribute	Qbrexza profile
Active ingredient	Glycopyrronium tosylate
Strength	2.4% glycopyrronium tosylate
Dosage form	Topical cloth
Administration	One cloth applied once daily to each underarm
FDA indication	Primary axillary hyperhidrosis
Minimum labeled age	9 years
Route	Topical
Product type	Single-use, premoistened cloth
Regulatory pathway	505(b)(1) new drug application
Therapeutic category	Dermatology; hyperhidrosis

The cloth format reduces dosing ambiguity and limits direct hand contact with the active ingredient. It also creates a product-specific manufacturing and intellectual-property platform that is more difficult to replicate than a simple topical solution.

What excipients are used in Qbrexza?

The Qbrexza label identifies citric acid, dehydrated alcohol, purified water, and sodium citrate among the inactive ingredients.[1] The product also relies on the cloth substrate and packaging system to deliver a reproducible amount of formulation to the axilla.

Excipient or component	Likely technical role
Purified water	Primary vehicle
Dehydrated alcohol	Solvent, rapid evaporation, wetting and drying behavior
Citric acid	pH adjustment and formulation stability
Sodium citrate	Buffering capacity and pH control
Cloth substrate	Dose delivery, surface distribution and contact control
Individual packaging	Moisture retention, dose protection and handling safety

The principal excipient strategy is functional rather than cosmetic. The formulation must remain chemically stable during storage, wet the cloth evenly, release the active during application, dry within a practical period, and limit unwanted transfer to the hands, eyes or adjacent skin.

The label does not establish that the inactive ingredients are individually responsible for Qbrexza’s clinical differentiation. The commercial value lies in the combined formulation, cloth, dose, package and instructions for use.

Which excipient functions are commercially important?

pH control

Citric acid and sodium citrate provide a buffered environment. pH affects glycopyrronium stability, skin tolerability, preservative requirements and the interaction between the liquid formulation and the cloth substrate.

A follow-on product could pursue a narrower pH range, lower buffering load or a less irritating buffer system. The commercial trade-off is that a material change in pH can affect chemical stability, extractables, skin sensation and bioequivalence.

Alcohol and evaporation

Dehydrated alcohol can improve wetting and promote rapid drying after application. It may also contribute to stinging, dryness or irritation, particularly in patients with sensitive or recently shaved skin.

Potential commercial opportunities include:

• Reducing alcohol content while maintaining drug solubility.
• Replacing part of the alcohol with a less irritating cosolvent.
• Controlling evaporation to improve contact time.
• Developing a low-sting formulation for pediatric or sensitive-skin use.
• Improving compatibility with the cloth and pouch.

Any change that alters evaporation, deposition or skin penetration could create a new formulation product rather than a straightforward generic.

Cloth wetting and drug release

The substrate must absorb and release a consistent amount of formulation. Important attributes include fiber composition, basis weight, liquid loading, surface energy, pore structure and mechanical strength.

A cloth with excessive absorption may retain drug and reduce delivery. A cloth with excessive release may increase runoff, hand transfer or ocular exposure. Uniformity across the cloth is a critical manufacturing-control issue.

Packaging moisture retention

The pouch must prevent evaporation and maintain dose uniformity through the labeled shelf life. Packaging changes can affect alcohol loss, water activity, cloth wetness and glycopyrronium concentration.

Commercially relevant packaging improvements include:

• Lower-cost high-barrier films.
• Child-resistant secondary packaging.
• More compact travel packaging.
• Improved tear-open performance for patients with limited dexterity.
• Packaging with lower material use.
• Unit-dose packaging compatible with automated dispensing systems.

Packaging is a potential lifecycle-management tool because it can improve usability without changing the active ingredient.

What formulation patents and manufacturing rights protect Qbrexza?

Qbrexza’s defensibility is likely distributed across several layers:

1. The glycopyrronium topical composition.
2. Treatment of hyperhidrosis with topical glycopyrronium.
3. The premoistened cloth dosage form.
4. Cloth loading and drug-release characteristics.
5. Single-use packaging.
6. Manufacturing processes for maintaining dose uniformity.
7. Methods that limit hand, ocular or facial exposure.
8. Pediatric use and specific administration instructions.

Patent protection for a topical cloth can extend beyond the active ingredient. Composition claims may be vulnerable to design-around using different excipients, while process, substrate and use claims may create separate barriers.

The FDA Orange Book should be used to identify current listed patents and their expiration dates for the approved product.[2] Patent status should be separated from regulatory exclusivity. A patent may remain enforceable after FDA exclusivity ends, while an unexpired patent may not block every alternative formulation.

Publicly available product information establishes the approved dosage form and formulation components. It does not, by itself, establish the complete scope or enforceability of the Qbrexza patent estate. Patent-family review should cover U.S. continuations, terminal disclaimers, priority claims, maintenance payments and litigation history.

When does Qbrexza lose exclusivity?

Qbrexza received FDA approval in 2018. The product’s five-year new chemical entity exclusivity would have expired in 2023, subject to the precise FDA classification of the active ingredient and approval date.[1,3]

The principal remaining exclusivity questions are patent-related:

• Orange Book-listed formulation or method-of-use patents.
• Unlisted patents covering cloth construction or manufacturing.
• Patent-term adjustment or patent-term extension.
• Pediatric exclusivity, if granted.
• Litigation settlements that delay or limit generic launch.
• Regulatory requirements for a follow-on product.

Because Qbrexza is a small-molecule drug, biosimilar exclusivity does not apply. A competing product would generally pursue an ANDA, a 505(b)(2) application, or an independent NDA rather than a biosimilar application.

What generic entry risks exist for Qbrexza?

A conventional generic cream, ointment or solution would not necessarily be substitutable for Qbrexza. The reference product is a cloth-based dosage form with a defined application method. The generic sponsor would need to address both pharmaceutical equivalence and the delivery system.

Potential entry routes include:

Entry route	Commercial implication
ANDA	Requires demonstration of equivalence to the reference product; substitutability depends on FDA standards for the dosage form
505(b)(2) NDA	Permits reliance on existing findings while supporting formulation, device or clinical differences
Independent NDA	Higher development cost but greater freedom to create a differentiated product
OTC switch	Unlikely near-term route because of anticholinergic safety and prescription-use requirements
Compounded topical	Limited commercial substitution and weaker quality controls

The most credible generic challenge would likely use the same active ingredient, concentration, route and cloth presentation while modifying selected excipients or packaging. A more divergent product could avoid some formulation claims but face additional clinical and regulatory requirements.

Are Paragraph IV challenges likely for Qbrexza?

A Paragraph IV filing is possible when an ANDA applicant asserts that an Orange Book-listed patent is invalid, unenforceable or not infringed. The business attractiveness of such a filing depends on the size of the Qbrexza market, the number of potential entrants, the remaining patent term and the cost of proving equivalence.

A Paragraph IV challenger would face several technical issues:

• Demonstrating consistent glycopyrronium delivery from the cloth.
• Matching the reference product’s liquid loading.
• Establishing stability in the final pouch.
• Controlling alcohol evaporation.
• Addressing ocular exposure and anticholinergic warnings.
• Showing equivalent performance despite excipient changes.
• Resolving any patent claims directed to the cloth or application method.

A formulation that uses the same active concentration but a different cloth or solvent system may create litigation risk under composition, dosage-form or method-of-use claims. A formulation with a different concentration or application schedule may require a separate clinical development strategy.

What are the best excipient-led lifecycle opportunities?

Lower-irritation Qbrexza-type products

The most direct opportunity is a lower-sting or lower-dryness formulation. Reducing alcohol or changing the solvent system could improve adherence, particularly among pediatric patients and users who shave the axilla.

The formulation must preserve glycopyrronium solubility, dose uniformity and drying performance. A lower-irritation product could support premium pricing if supported by comparative tolerability data.

Pediatric-focused delivery

Qbrexza is approved for patients aged 9 and older. A pediatric-focused product could use:

• Smaller cloth dimensions.
• Tighter liquid-loading specifications.
• Packaging that reduces accidental exposure.
• Application instructions designed for caregiver use.
• A lower-irritation vehicle.
• Tactile or visual guidance for correct application.

A pediatric presentation could be developed as a line extension, subject to FDA requirements for the proposed change.

Preapplication and postapplication skin care

A companion product could address dryness or irritation without altering Qbrexza itself. Possibilities include an antiperspirant-compatible moisturizer, a barrier-support product, or a postapplication skin-care product.

The commercial constraint is interaction. A moisturizer or occlusive product may change glycopyrronium absorption, drying or distribution. Co-packaging would require compatibility and labeling analysis.

Extended-use or reusable delivery

A reusable applicator could reduce packaging waste, but it would introduce cleaning, dose carryover, microbial control and accidental-exposure issues. It is less likely to be a near-term generic strategy than an optimized single-use cloth.

Combination treatment

Combination products pairing topical glycopyrronium with another hyperhidrosis therapy could target patients with inadequate response. Such products would require clinical evidence and could increase local irritation or systemic anticholinergic exposure.

The stronger commercial opportunity is usually sequential treatment rather than a fixed-dose combination: topical glycopyrronium for daily control, with other therapies used for resistant disease.

How does Qbrexza compare with competing hyperhidrosis products?

Product category	Primary advantage	Main limitation	Excipient opportunity
Qbrexza cloth	Prescription topical delivery with once-daily use	Cost, irritation, anticholinergic precautions	Lower-sting vehicle, improved cloth and packaging
Aluminum chloride products	Established topical option	Irritation and variable adherence	Buffered, lower-irritation vehicles
Topical oxybutynin	Alternative anticholinergic approach	Different safety and formulation profile	Transdermal delivery and skin tolerability
Oral anticholinergics	Systemic treatment for broader disease	Systemic adverse effects	Limited excipient relevance
Botulinum toxin	Strong efficacy for selected patients	Injections, cost and duration	Reconstitution and injection-system improvements
Energy-based devices	Office-based treatment	Capital cost and access	Gel, coupling medium and disposable handpiece opportunities

Qbrexza’s competitive advantage is convenience and localized administration. Its main weakness is that the same anticholinergic mechanism that enables efficacy can produce dry mouth, blurred vision, urinary effects or heat-related safety concerns if the drug reaches unintended sites or is systemically absorbed.

What is the FDA regulatory status of Qbrexza?

Qbrexza is an FDA-approved prescription drug for primary axillary hyperhidrosis. The approved label includes warnings concerning accidental transfer to the eyes and systemic anticholinergic effects.[1]

For an excipient-modified product, the regulatory pathway depends on the extent of change:

• Minor packaging or manufacturing changes may be handled through post-approval supplements.
• A new cloth substrate may require comparative performance and stability data.
• A materially different vehicle may require a 505(b)(2) application.
• A new indication, age group or dosing schedule may require clinical evidence.
• A product that cannot demonstrate pharmaceutical equivalence may not qualify for ANDA approval.

The cloth is a central part of the dosage form. FDA review would likely focus on content uniformity, release, extractables and leachables, microbial quality, pouch integrity, in-use handling and accidental-exposure controls.

What is the commercial opportunity for manufacturers and licensors?

The most attractive licensing targets are companies with expertise in:

• Nonwoven and woven drug-delivery substrates.
• High-barrier unit-dose packaging.
• Solvent-reduced topical formulations.
• Pediatric dermatology.
• Transdermal and mucosal drug delivery.
• Contract manufacturing of premoistened wipes and cloths.
• Skin-tolerability testing and human-factor studies.

A manufacturer could pursue three commercial models:

1. Supply the reference product or a licensed product under contract.
2. License a differentiated cloth or excipient platform to the product owner.
3. Develop an independent follow-on product using an ANDA, 505(b)(2) or NDA strategy.

The revenue opportunity is constrained by the size of the hyperhidrosis market and the limited disclosure of Qbrexza-specific sales. Journey Medical has marketed Qbrexza in the United States, but product-level revenue and margin data are not consistently disclosed in public filings. Market value should therefore be assessed through prescription volume, payer coverage, refill persistence and net price rather than headline list price.

How strong is the Qbrexza patent estate?

Qbrexza has a stronger defensibility profile than a simple topical solution because protection may cover the formulation, cloth and use instructions together. The estate is weaker against a product that uses a different dosage form and develops independent clinical evidence, although that route is more expensive.

Estate layer	Relative strategic value
Active-ingredient claims	Limited if glycopyrronium itself is established
Topical composition claims	Moderate; excipient design-arounds may be possible
Cloth dosage-form claims	High if claims cover dose delivery and substrate structure
Packaging claims	Moderate; often vulnerable to alternative package designs
Manufacturing claims	Moderate to high where process reproducibility is difficult
Method-of-use claims	Moderate; strength depends on claim scope and labeling
Pediatric claims	Potentially valuable if separately protected

The key commercial question is whether a challenger can reproduce the clinical performance of the cloth without practicing valid claims directed to the formulation or delivery system. That question requires claim-charting against the active Orange Book and patent-family records.

Key Takeaways

• Qbrexza is a 2.4% glycopyrronium tosylate single-use topical cloth for primary axillary hyperhidrosis.
• Its listed inactive ingredients include purified water, dehydrated alcohol, citric acid and sodium citrate.
• The most valuable excipient functions are pH control, alcohol-mediated wetting and evaporation, drug release from the cloth, and pouch moisture retention.
• The strongest lifecycle opportunities are lower-irritation formulations, pediatric packaging, improved cloth substrates and high-barrier unit-dose systems.
• Qbrexza is a small-molecule product, so biosimilar risk does not apply.
• Generic entry would require more than active-ingredient matching because the cloth is part of the dosage form.
• ANDA, 505(b)(2) and independent NDA strategies present different balances of substitution, development cost and patent risk.
• The remaining commercial barrier is likely the combined formulation, cloth, packaging, manufacturing and method-of-use patent position rather than new chemical entity exclusivity.
• Product-level revenue exposure is difficult to quantify from public disclosures and should be modeled through prescription and reimbursement data.

FAQs

Can Qbrexza excipients be changed without conducting new clinical trials?

Some minor manufacturing or packaging changes may be managed through post-approval supplements. A material change to the solvent system, pH, cloth or drug-release profile may require comparative performance, pharmacokinetic, local tolerability or clinical data.

Is glycopyrronium tosylate the same as glycopyrrolate?

They are related naming conventions for the glycopyrronium active moiety. Qbrexza is labeled as glycopyrronium tosylate, while glycopyrrolate is commonly used in other dosage forms and jurisdictions. Regulatory equivalence depends on the specific salt, strength, dosage form and FDA standards.

Could a Qbrexza competitor use a cream instead of a cloth?

Yes, but a cream would likely require a separate equivalence and regulatory strategy. It may avoid some cloth-related claims while losing the reference product’s single-use delivery and administration characteristics.

Does Qbrexza have biosimilar competition?

No. Qbrexza contains a chemically synthesized small-molecule active ingredient. Potential competitors would be generics, 505(b)(2) products or independently approved topical drugs.

What is the most defensible excipient innovation for a Qbrexza follow-on product?

A coordinated platform combining a lower-irritation vehicle, controlled cloth loading, high-barrier packaging and validated dose-release performance is more defensible than changing a single inactive ingredient. The strongest protection would combine formulation, substrate, manufacturing and use claims.

References

1. U.S. Food and Drug Administration. (2018). Qbrexza (glycopyrronium) cloth, 2.4%: Prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
3. U.S. Food and Drug Administration. (n.d.). New chemical entity exclusivity and regulatory exclusivity provisions.